Redx Pharma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Redx Pharma - overview
Established
2010
Location
Macclesfield, -, UK
Primary Industry
Pharmaceuticals
About
Based in the UK, Redx Pharma Limited develops targeted small-molecule medicines for fibrotic disease and cancer. Based in Macclesfield, UK and founded in 2010 by its co-founder Neil Murray, Peter Jackson, Derek Lindsay, Redx Pharma Limited previously known as Redx Pharma Plc, conducts drug discovery and clinical development focused primarily on fibrotic diseases. The company develops small-molecule drug candidates targeting the ROCK pathway and Discoidin Domain Receptors. In August 2026, Redx Pharma Plc raised USD 36 million in series A funding led by Abingworth, with participation from other investors British Business Bank, NextBio,5AM Ventures and Redmile Group.
Redx Pharma researches and develops novel small-molecule medicines for fibrosis and cancer. Its pipeline includes Zelasudil (RXC007) for idiopathic pulmonary fibrosis, RXC008 for Crohn's disease-related fibrosis, and RXC004 for cancer treatment. The company also provides drug discovery, translational science, and clinical development expertise. The company generates revenue through research collaborations, licensing agreements, upfront payments, milestone payments, and potential royalties from pharmaceutical partners.
Strategic partnerships with companies such as Jazz Pharmaceuticals and AstraZeneca support development programs while providing non-dilutive funding for clinical research and commercialization activities. The company will use the September 2026 funding to support Phase 2 development of RXC008 for fibrostenotic Crohn’s disease.
Current Investors
Sofinnova Partners, Redmile Group, Moulton Goodies Limited
Primary Industry
Pharmaceuticals
Sub Industries
Biotechnology, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.redxpharma.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Redx Pharma - timeline of key events
Redx Pharma - financials
| Fiscal Year Ended | Sep 30, 2011 | Sep 20, 2012 | Sep 30, 2013 | Sep 30, 2014 | Sep 30, 2015 | Sep 30, 2016 | Sep 30, 2017 | Sep 30, 2018 | Sep 30, 2019 | Sep 30, 2020 | Sep 30, 2021 | Sep 30, 2022 | Sep 30, 2023 | Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | 2,400,000 | - | - | 30,474,000 | 129,000 | 3,131,000 | 5,685,000 | 10,035,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | (99.6%) | 2327.1% | 81.6% | 76.5% | - | - | - |
| EBITDA (USD) | - | - | - | (3,366,174) | (9,292,000) | (14,686,000) | 2,303,000 | (10,005,000) | (6,154,000) | (7,536,000) | (19,112,000) | - | - | - |
| Operating Income (USD) | - | - | - | (3,634,336) | (9,431,000) | (14,948,000) | 1,976,000 | (10,169,000) | (6,245,000) | (8,201,000) | (19,745,000) | - | - | - |
| Operating Margin | - | - | - | (151.4%) | - | - | 6.5% | (7882.9%) | (199.5%) | (144.3%) | (196.8%) | - | - | - |
| % EBITDA Margin | - | - | - | (140.3%) | - | - | 7.6% | (7755.8%) | (196.6%) | (132.6%) | (190.5%) | - | - | - |
| NET Income (USD) | (2,016,115) | (1,688,278) | (1,226,047) | (2,964,196) | (8,175,000) | (15,521,000) | 1,528,000 | (8,845,000) | (4,318,000) | (9,213,000) | (21,576,000) | - | - | - |
| % Net Margin | - | - | - | (123.5%) | - | - | 5.0% | (6856.6%) | (137.9%) | (162.1%) | (215.0%) | - | - | - |
Redx Pharma - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A | Completed | Redx Pharma | - | ||||||||
| PIPE | Completed | Redx Pharma | - | ||||||||
| Venture Debt | Completed | Redx Pharma | - | ||||||||
| Trade Sale | Completed | Redx Pharma | - | ||||||||
| Venture Debt | Completed | Redx Pharma | - |
Displaying 1 - 5 of 14
Redx Pharma - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.